摘要
黑素瘤占所有癌症的2-3%,其中95%来自皮肤,而只有5%是非皮肤黑素瘤。尽管有最佳的手术管理,但局部和全身复发的风险依然很高,特别是在高危患者(淋巴结阳性或淋巴结阴性T3b,T4a / b)中更是如此。我们对2000年至2015年6月期间主要发表和正在进行的I / II / III期临床试验进行了系统评价,对皮肤黑素瘤的辅助治疗进行了研究。干扰素仍然是目前唯一的选择。考虑到EORTC 18701试验在无病生存期(DFS)方面的积极结果,而Ipilimumab在这种情况下代表了一个可能的突破,而有关OS的数据尚未确定。最近对黑素瘤生物学认识的进展导致了MAPK通路在黑素瘤发展中的作用。 基于这些特征,B-RAF抑制剂及其与免疫疗法的组合可以代表即将到来的治疗策略。
关键词: 辅助治疗,生物化疗,免疫治疗,干扰素,黑色素瘤,放疗,靶向治疗。
图形摘要
Current Cancer Drug Targets
Title:Melanoma Adjuvant Treatment: Current Insight and Clinical Features
Volume: 18 Issue: 5
关键词: 辅助治疗,生物化疗,免疫治疗,干扰素,黑色素瘤,放疗,靶向治疗。
摘要: Melanoma represents 2-3% of all cancers, 95% of them arise from skin, while only 5% are non-cutaneous melanoma. Despite an optimal surgery management, the risk of a local and systemic relapse remains high, particularly in high-risk patients (node-positive or node-negative T3b, T4 a/b). We conducted a systematic review of the main published and ongoing phase I/II/III trials between 2000 and June 2015 on the adjuvant treatment of cutaneous melanoma. The IFN remains the only option currently available for this aim. Ipilimumab represents a possible breakthrough in this setting, considering the positive results of the EORTC 18701 trials in terms of disease free survival (DFS), while data regarding OS are pending. Recent advances in the understanding of the biology of melanoma result in the identification of MAPK pathway role in the melanoma development.
Based on these features, B-RAF inhibitors and their combination with immunotherapy could represent the upcoming therapeutic strategy.
Export Options
About this article
Cite this article as:
Melanoma Adjuvant Treatment: Current Insight and Clinical Features, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009617666170208163714
DOI https://dx.doi.org/10.2174/1568009617666170208163714 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical Design Human Saliva Metabolome for Oral Lichen Planus Biomarker Identification
Recent Patents on Anti-Cancer Drug Discovery Biologically Active Natural Products of the Genus Callicarpa
Current Bioactive Compounds Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Current Signal Transduction Therapy Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Current Cancer Drug Targets Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology Ultraviolet B Regulation of Transcription Factor Families: Roles of Nuclear Factor-kappa B (NF-κB) and Activator Protein-1 (AP-1) in UVB-Induced Skin Carcinogenesis
Current Cancer Drug Targets Antitumor Effects of Interferon-Alpha on Cell Growth and Metastasis in Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Metabolomics as a Tool for Drug Discovery and Personalised Medicine. A Review
Current Topics in Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Docking Studies Against EGFR Tyrosine Kinase of 3,5-bis(substituted benzylidene)-1- ethylpiperidin-4-one Analogues
Letters in Organic Chemistry Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry